A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Mar 2013

At a glance

  • Drugs Sapitinib (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 31 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov record.
    • 14 Feb 2012 Additional lead trial investigator (Serban Ghiorghiu) identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top